Celia Morgan
Professor of Psychopharmacology, University of Exeter
Speaking at 1st KAP International Association Summit
Ketamine research and treatment
One of Europe's most-cited ketamine researchers. Leads the Ketamine for Reduction of Alcoholic Relapse trial and co-authored a 2021 systematic review (with David Nutt and others) on ketamine for mental health and substance use disorders. Holds an Honorary Readership at UCL alongside her Exeter chair.
Public Company Affiliation
Solvonis Therapeutics plc (formerly Awakn Life Sciences Corp.) LSE: SVNS
Awakn Life Sciences Corp. — where Morgan was named Head of Ketamine-Assisted Psychotherapy for the Alcohol Use Disorder practice per 2021–2022 announcements — was acquired by Solvonis Therapeutics plc, completing May 28, 2025; Awakn delisted from the CSE and its ketamine programs now sit under Solvonis (LSE: SVNS). Morgan's specific current role within Solvonis isn't independently confirmed beyond the original Awakn announcements.